Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02177838 · ClinicalTrials.gov registry record · NA
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02177838 is a NA study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 8 participants.
The verdict
NCT02177838, a NA study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- BIOLOGICAL cetuximab
- RADIATION external beam radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2019-08-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02177838
The ClinicalTrials.gov registry entry for NCT02177838 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02177838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02177838 about?
NCT02177838 is a clinical study titled "Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer". This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells....
What is the current status of trial NCT02177838?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2015-03-25. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT02177838?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), cetuximab (BIOLOGICAL), external beam radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT02177838?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.